Related Experiment Video
Updated: May 20, 2026

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
Published on: April 21, 2023
Antibacterial activities of iron chelators against common nosocomial pathogens
Mitchell G Thompson1, Brendan W Corey, Yuanzheng Si
1Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Abstract:
The activities of iron chelators (deferoxamine, deferiprone, Apo6619, and VK28) were evaluated against type strains of Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli. Deferiprone, Apo6619, and VK28 each inhibited growth in standard and RPMI tissue culture medium, while deferoxamine had no effect. Additionally, time-kill assays revealed that VK28 had a bacteriostatic effect against S. aureus. Therefore, these newly developed iron chelators might provide a nontraditional approach for treatment of bacterial infections.
Insights
New iron chelators, deferiprone, Apo6619, and VK28, show promise in inhibiting bacterial growth. VK28 demonstrated bacteriostatic effects against Staphylococcus aureus, suggesting a novel treatment approach for infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Bacterial infections pose a significant global health threat, necessitating novel therapeutic strategies.
- Iron is essential for bacterial growth and virulence, making iron chelation a potential antimicrobial approach.
Purpose of the Study:
- To evaluate the in vitro activity of novel iron chelators against key bacterial pathogens.
- To determine the efficacy of deferiprone, Apo6619, and VK28 in inhibiting bacterial growth and survival.
Main Methods:
- Standard antimicrobial susceptibility testing was performed.
- Time-kill assays were conducted to assess bactericidal or bacteriostatic activity.
- Evaluated iron chelators included deferoxamine, deferiprone, Apo6619, and VK28.
- Tested bacterial strains included Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli.
Main Results:
- Deferiprone, Apo6619, and VK28 demonstrated significant inhibition of bacterial growth across multiple strains.
- Deferoxamine showed no significant antimicrobial activity in this study.
- VK28 exhibited a bacteriostatic effect against Staphylococcus aureus.
Conclusions:
- Novel iron chelators, specifically deferiprone, Apo6619, and VK28, possess potent in vitro antibacterial activity.
- These compounds represent a promising, non-traditional therapeutic avenue for combating bacterial infections.
- Further research into iron chelator-based therapies is warranted for infectious disease treatment.
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Clinical Significance of Antibiotic Resistance
Antimicrobial Effectiveness
Hand hygiene
Hand washing...
Inhibitors of Bacterial DNA Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...

